Of the 16 anti-PD-1/PD-L1–naïve patients with NSCLC, 14 were evaluable for response, with an ORR of 35.7% (95% CI 12.8 to 64.9; n=5/14), all of which were PRs; SD was observed in an additional eight patients (57.1%; table 5). The gene discussed is CD274; the disease is non-small cell lung carcinoma.